Function-first discovery of high affinity monoclonal antibodies using Nanovial-based plasma B cell screening.

ABSTRACT: Antibody discovery technologies, essential for research and therapeutic applications, have evolved significantly since the development of hybridoma technology. Various in vitro (display) and in vivo (animal immunization and B cell-sequencing) workflows have led to the discovery of antibodies against diverse antigens. Despite this success, standard display and B-cell sequencing-based technologies are limited to targets that can be produced in a soluble form. This limitation inhibits the screening of function-inducing antibodies, which require the target to be expressed in cells to monitor function or signaling, and antibodies targeting proteins that maintain their physiological structure only when expressed on cell membranes, such as G-protein coupled receptors (GPCRs). A high-throughput tw

SUBMITTER: Challa D 

PROVIDER: S-EPMC11370415 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature